SS Innovations Stock Price, News & Analysis

SS Innovations International (NASDAQ: SSII), a surgical robotics technology company, will ring the Nasdaq opening bell on June 3, 2025, celebrating their April 2025 Nasdaq uplisting. The ceremony will be led by CEO Dr. Sudhir Srivastava and company leadership. The event also marks the milestone of over 4,000 successful robotic surgeries completed using their SSi Mantra system across more than 100 surgery types, with zero complications. The SSi Mantra, designed as a cost-effective surgical robotic system, has gained adoption in India and six other countries. The company is actively pursuing expansion into new markets, including the EU and US, with a mission to make advanced robotic surgery more accessible and affordable globally.

SS Innovations (NASDAQ: SSII) has achieved a significant milestone with its SSi Mantra surgical robotic system, successfully completing over 4,000 robotic surgeries across more than 100 types of procedures with zero complications. Notable achievements include 215 cardiac surgical procedures, with six performed via telesurgery across India using the SSi Mantra 3 system.

The system is currently approved in seven countries including India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, and Ukraine. The company is pursuing market expansion with expected European Union CE Mark decision by late 2025 and FDA approval targeted for first half of 2026. The SSi Mantra system supports various surgical specialties including general surgery, urology, gynecology, cardiac, gastrointestinal, thoracic, head and neck, and breast and plastic procedures.

SS Innovations (NASDAQ: SSII) reported strong Q1 2025 financial results with record quarterly revenue of $5.1 million, up 40.8% year-over-year. The growth was driven by increased sales of their SSi Mantra 3 surgical robotic system. Key highlights include: - 15 new system installations (66.7% increase YoY) - Gross margin expanded to 21.23% - Net loss improved to $5.7 million ($0.03/share) vs $9.8 million ($0.06/share) in Q1 2024 - Cumulative installed base reached 78 units with 3,568 total surgeries performed - Cash position of $15.9 million with zero long-term debt The company achieved a significant milestone with its Nasdaq uplisting in April 2025 and plans to submit a De Novo FDA application for SSi Mantra 3 by July 2025, while pursuing EU CE Mark approval by late 2025.

SS Innovations International (NASDAQ: SSII) announced plans to submit a De Novo Classification Request to the FDA for its SSi Mantra 3 surgical robotic system in July 2025. The company has demonstrated significant market traction with 80 SSi Mantra systems installed across 75 hospitals since August 2022, facilitating over 3,800 surgeries. The newer SSi Mantra 3 version, launched in June 2024, has 37 installations and has been used in more than 750 procedures, including 70 cardiac cases, with no device-related complications.

The FDA submission will seek approval for multiple surgical specialties including urology, gynecology, general surgery, and thoracic and cardiac surgery. The system is currently approved in six countries, and the company is simultaneously pursuing EU CE Mark approval.

SS Innovations (NASDAQ: SSII) has reiterated its Q1 2025 guidance and provided Q2 2025 order trends. The company installed 14 SSi Mantra surgical robotic systems in Q1 2025, bringing the total installed base to 78 systems as of March 31, 2025. Expected Q1 2025 revenue is approximately $6.4 million with a 45% gross margin. As of April 30, 2025, the installed base reached 80 systems across 75 hospitals, with over 3,800 surgeries completed, including more than 200 robotic cardiac surgeries. System orders in April 2025 totaled 9 units, representing a 200% increase from April 2024. The company plans to report Q1 2025 financial results around May 15, 2025.

SS Innovations International (NASDAQ: SSII), a surgical robotics technology company, has announced a planned CFO transition. Arvind Palaniappan has been appointed as Interim CFO effective May 1, 2025, replacing Anup Sethi, who served as CFO during the company's growth phase. Under Sethi's seven-year tenure, the company successfully launched over 80 surgical robotic systems in India and internationally, and recently achieved a milestone with its Nasdaq uplisting on April 25. The company has initiated a search for a permanent CFO, while Sethi will remain available in an advisory capacity during the transition period.

SS Innovations International (SSII) has received approval to uplist from OTC to Nasdaq Capital Market, with trading set to commence on April 25, 2025, under the same ticker 'SSII'. The company, focused on affordable surgical robotic technologies, reported significant achievements with its SSi Mantra surgical robotic system:

Key highlights include:

• Installation of 80 systems across 75 hospitals in India and other countries
• 3,500+ successful surgeries, including 195+ cardiac procedures with zero device-related complications
• First Indian company to receive CDSCO approval for telesurgery
• Completed 16 telesurgeries, including world's first robotic cardiac telesurgeries at distances up to 1,200 miles

The company reported strong financial performance with revenue of $20.6 million for 2024, a 251% increase from 2023's $5.9 million, and improved gross margin from 12.3% to 40.9%. SSII is pursuing EU CE Mark and U.S. FDA approval, expected in late 2025 and early 2026, respectively.

SS Innovations International (SSII) has reported significant achievements in 2024, with its SSi Mantra surgical robotic system completing over 3,500 surgeries across 80 installations in 75 hospitals. The company sold 37 systems and installed 8 more on a Pay-Per-Use Lease model in 2024.

Preliminary unaudited results show expected 2024 revenues of over US$22 million, representing a nearly four-fold increase from 2023. Gross margins improved from 12.30% to 36.90%. For Q1 2025, SSII anticipates reaching 78 installations with estimated revenues of US$6.4 million and 45% gross margin.

Key achievements include: zero device-related complications across all procedures, successful telesurgery implementation with 16 procedures completed, expansion of manufacturing capacity to 20 units monthly, training of over 750 surgeons, and regulatory approvals in multiple countries. The company expects FDA and CE approvals by late 2025 or early 2026.

SS Innovations International (OTC: SSII) has secured regulatory approvals for its SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine. The company partnered with RBGM Medical Express Sales Inc. in Manila and Loran Group in Kiev for distribution.

The Philippines market, with nearly 4,000 hospitals, represents a significant opportunity for expanding robotic surgery access. In Ukraine, despite ongoing conflict and damaged medical facilities, the Certificate of Conformity approval positions SSII to participate in the country's medical infrastructure rebuilding efforts.

The SSi Mantra 3 system features 3-5 robotic arms, 3D 4K monitoring, and over 40 different types of robotic endo-surgical instruments. It has been clinically validated in India across 80+ surgical procedures. The company anticipates receiving FDA and CE Mark approvals in the second half of 2025.